K. N. Verpoort - Concepedia

Concepedia

Author

K. N. Verpoort

Leiden University Medical Center

Also Known As

K N Verpoort, K. N. Verpoort, K. Verpoort, Kirsten N Verpoort, Kirsten N. Verpoort

20

Publications

2.3K

Citations

16

H-Index

15

Concepts

All Affiliations

Leiden University Medical Center Radboud University Nijmegen

KN

About

K. N. Verpoort is an author at Leiden University Medical Center specializing in medicine, molecular diagnostics, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	97
2	Public Health	1	1	80
3	Biostatistics	1	1	17
4	Epidemiology	1	1	80
5	Rheumatology	1	1	80

K. N. Verpoort

×

15

Publications

2.3K

Citations

15

H-Index

	Year	Citations
Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis Annette H M van der Helm–van Mil, K. N. Verpoort, Ferdinand C. Breedveld, Arthritis Research & Therapy	2005	474
The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis Annette H M van der Helm–van Mil, K. N. Verpoort, Ferdinand C. Breedveld, Arthritis & Rheumatism	2006	348
Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis Diane van der Woude, Solbritt Rantapää‐Dahlqvist, A. Ioan-Facsinay, Annals of the Rheumatic Diseases	2010	317
Isotype distribution of ANTI–CYCLIC citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response K. N. Verpoort, Cornelia M. Jol‐van der Zijde, Ellen A. M. Papendrecht-van der Voort, Arthritis & Rheumatism	2006	210
Association of HLA–DR3 with anti–cyclic citrullinated peptide antibody–negative rheumatoid arthritis K. N. Verpoort, Floris A. van Gaalen, Annette H M van der Helm–van Mil, Arthritis & Rheumatism	2005	175
The HLA–DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide Annette H M van der Helm–van Mil, K. N. Verpoort, Saskia le Cessie, Arthritis & Rheumatism	2007	140
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis Klaus Machold, Robert Landewé, Josef S Smolen, Annals of the Rheumatic Diseases	2010	134
Fine specificity of the anti–citrullinated protein antibody response is influenced by the shared epitope alleles K. N. Verpoort, Kiki Cheung, Andreea Ioan‐Facsinay, Arthritis & Rheumatism	2007	124
Progression of joint damage in early rheumatoid arthritis: Association with HLA–DRB1, rheumatoid factor, and anti–citrullinated protein antibodies in relation to different treatment strategies Jeska K de Vries‐Bouwstra, Y P M Goekoop-Ruiterman, K. N. Verpoort, Arthritis & Rheumatism	2008	101
Undifferentiated arthritis--disease course assessed in several inception cohorts. K. N. Verpoort, Heleen van Dongen, Cornelia F Allaart, PubMed Rheumatoid DisorderRheumatologyEpidemiologyUa PatientsMedicine	2005	80

Page 1